TRIAMCINOLONE ACETONIDE paste

国家: 美国

语言: 英文

来源: NLM (National Library of Medicine)

有效成分:

Triamcinolone Acetonide (UNII: F446C597KA) (Triamcinolone - UNII:1ZK20VI6TY)

可用日期:

Physicians Total Care, Inc.

INN（国际名称）:

Triamcinolone Acetonide

组成:

Triamcinolone Acetonide 1 mg in 1 g

给药途径:

DENTAL

处方类型:

PRESCRIPTION DRUG

疗效迹象:

Triamcinolone Acetonide Dental Paste USP, 0.1% is indicated for adjunctive treatment and for the temporary relief of symptoms associated with oral inflammatory lesions and ulcerative lesions resulting from trauma. Triamcinolone acetonide dental paste is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation; it is also contraindicated in the presence of fungal, viral, or bacterial infections of the mouth or throat.

產品總結:

Triamcinolone Acetonide Dental Paste USP, 0.1% is supplied in tubes containing 5 g of dental paste (NDC 54868-2742-0). Keep tightly closed. Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature].

授权状态:

Abbreviated New Drug Application

产品特点

TRIAMCINOLONE ACETONIDE - TRIAMCINOLONE ACETONIDE PASTE
PHYSICIANS TOTAL CARE, INC.
----------
TRIAMCINOLONE ACETONIDE
DENTAL PASTE USP, 0.1%
RX ONLY
DESCRIPTION
Triamcinolone Acetonide Dental Paste USP, 0.1%, contains the
corticosteroid triamcinolone acetonide
in an adhesive vehicle suitable for application to oral tissues.
Triamcinolone acetonide is designated
chemically as 9-fluoro-11β, 16α, 17, 21-tetrahydroxypregna-1,
4-diene-3, 20-dione cyclic 16, 17-acetal
with acetone. The structural formula of triamcinolone acetonide is as
follows:
C
H FO MW 4 34 .50
Each gram of triamcinolone acetonide dental paste contains 1 mg
triamcinolone acetonide in an emollient
dental paste containing gelatin, pectin, and carboxymethylcellulose
sodium in a plasticized hydrocarbon
gel (a polyethylene and mineral oil gel base).
CLINICAL PHARMACOLOGY
Like other topical corticosteroids, triamcinolone acetonide has
anti-inflammatory, antipruritic, and
vasoconstrictive properties. The mechanism of the anti-inflammatory
activity of the topical steroids, in
general, is unclear. However, corticosteroids are thought to act by
the induction of phospholipase A
inhibitory proteins, collectively called lipocortins. It is postulated
that these proteins control the
biosynthesis of potent mediators of inflammation such as
prostaglandins and leukotrienes by inhibiting
the release of their common precursor, arachidonic acid. Arachidonic
acid is released from membrane
phospholipids by phospholipase A .
PHARMACOKINETICS
The extent of absorption through the oral mucosa is determined by
multiple factors including the
vehicle, the integrity of the mucosal barrier, the duration of
therapy, and the presence of inflammation
and/or other disease processes. Once absorbed through the mucous
membranes, the disposition of
corticosteroids is similar to that of systemically administered
corticosteroids. Corticosteroids are
bound to the plasma proteins in varying degrees. Corticosteroids are
metabolized primarily in the liver
and are then excreted by the kidneys